Dynavax Technologies Corporation (DVAX) stock has fallen 11.03% over the past week and gets a Bearish rating from InvestorsObserver's Sentiment Indicator.
What is Stock Sentiment?
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With DVAX Stock Today?
Dynavax Technologies Corporation (DVAX) stock is down -0.84% while the S&P 500 has risen 0.09% as of 10:53 AM on Thursday, Dec 10. DVAX is lower by -$0.04 from the previous closing price of $4.64 on volume of 552,541 shares. Over the past year the S&P 500 is up 17.36% while DVAX is lower by -33.24%. DVAX lost -$1.08 per share in the over the last 12 months.
To screen for more stocks like Dynavax Technologies Corporation click here.
More About Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax operates in the business segment the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.
Click Here to get the full Stock Score Report on Dynavax Technologies Corporation (DVAX) Stock.
